Novalis Biotech announces acquisition of Doc.ai by Sharecare
Novalis Biotech, an early stage venture capital investor in technologies to revolutionize healthcare, announced that portfolio company doc.ai, a Silicon Valley-based company accelerating digital transformation in healthcare, has entered an agreement to be bought by Sharecare.
“Doc.ai was one of our first investments and over the past five years has gone from strength to strength,” said Jan Van den Berghe, co-founder of Novalis. “We want to congratulate the whole doc.ai team and anticipate the combination with Sharecare will have a dramatic impact on how digital health will play a key role in delivery healthcare in the future.”
“The investment in doc.ai has been a huge success for Novalis,” said Wim van Criekinge, co-founder of Novalis. “We are continuing looking for the next investments that we believe with transform delivery of healthcare as part of our next fund, the Novalis Acceleration Fund, which is due to close soon.”
Novalis invests early and focuses on capital light ideas, where a relatively small investment can create significant value through the use of software, IP, tools, and other technology that can serve and benefit healthcare. Leveraging extensive academic networks, Novalis translates innovation to viable companies that able to deliver on the founding scientific promise.
About Novalis
Novalis provides seed funding and ongoing support to biotechnology and life sciences companies. Novalis incubates and advances its own ideas or supports existing innovative life science start-ups. The company’s core competence lies in the interaction between bioinformatics, genomics, and digitalization in the life sciences industry. Novalis strongly believes in applying innovative information technology to advance the prevention, diagnosis, or treatment of a disease. For more information, please visit www.noval.is.